Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The standard treatment strategy for locally advanced (stage IVA) and metastatic (stage IVB)
nasopharyngeal carcinoma has not been defined yet. Generally induction chemotherapy is given
to those patients in order to shrink the tumor volume and facilitate the following radiation
therapy. Thus, in this study, the investigators use the combination of
Docetaxel+Cisplatin+Xeloda (DCX) to treat locally advanced and metastatic nasopharyngeal
carcinoma patients, in order to evaluate the efficacy and safety profiles.